ThromboGenics NV (EBR: THR) has strengthened its senior leadership team with the appointment of Dr Susan Schneider as chief medical officer, and Vincaine Vangeersdaele as chief commercial officer, the company announced on Wednesday.

Dr Schneider has almost 15 years' experience in clinical drug development. Her most recent role prior to joining ThromboGenics was VP & therapeutic area head of retina & glaucoma at Allergan (NYSE: AGN).

At ThromboGenics, Dr Schneider will be responsible for the development and execution of the company's global clinical and medical programmes that are focused on its industry-leading pipeline of drug candidates targeting diabetic eye disease.

Vincaine Vangeersdaele joined the company as CCO, bringing more than 15 years' experience from a variety of sales and marketing leadership roles in the global pharmaceutical industry. Her latest role saw her serve as the head of the Ophthalmology Franchise Europe at Novartis AG (VTX: NOVN).

As CCO at ThromboGenics, Vangeersdaele will lead and develop the overall commercial strategy for the company's recently formed global JETREA business unit, which was created after ThromboGenics regained the full global rights to JETREA from Novartis. She will also be responsible for leading the strategic marketing activities for any new compound that emerges from the company's clinical development pipeline, focused on diabetic eye disease.